Acalabrutinib and rituximab for mantle cell lymphoma – pro
T reatment with acalabrutinib and rituximab can yield early complete responses (CRs) in older patients with previously untreated mantle cell lymphoma (MCL).Among these patients, the overall response rate (ORR), based on Lugano criteria and PET-CT alone, was 94.4% in the TN cohort compared with 85.0% in the R/R cohort. Further, based on the Lugano criteria, a complete response (CR) rate of 77.8% was seen in the TN cohort and 70.0% in the R/R cohort, compared with a CR rate observed on PET/CT alone of 88.9% vs 80.0% in the TN and R/R cohorts, respectively. These numbers are so dramatic that this treatment became quickly adopted in clinical care.
Jain P, Ok CY, Fetooh A, et al. Acalabrutinib with rituximab as first-line therapy for older patients with mantle cell lymphoma–A phase II clinical trial. ICML 2023. June 13-17, 2023. Abstract 99.
Girard J, Reneau J, Devata S, Wilcox RA, Kaminski MS, Mercer J, Carty S, Phillips TJ. Evaluating Acalabrutinib In The Treatment Of Mantle Cell Lymphoma: Design, Development, And Place In Therapy. Onco Targets Ther. 2019 Sep 30;12:8003-8014.